Cellbank Inc. (Location: Chuo-ku, Tokyo; Representative Director: Genji Hojo; hereinafter "the Company"), which operates a specified cell processing business, has partnered with The Plus Plastic Surgery Daikanyama (Location: Shibuya-ku, Tokyo; Director: Daikan Ike) as a partner medical institution, and has commenced the provision of autologous cultured dermal fibroblasts for skin regeneration therapy (hereinafter "regenerative medicine for skin"). The Plus Plastic Surgery, with branches in Korea, Tokyo, and Nagoya, is a technology-driven clinic staffed exclusively by board-certified specialists of the Japan Society of Plastic and Reconstructive Surgery. They aim to provide high-quality cosmetic medicine by fusing advanced techniques recognized in domestic and international academic societies with active technical exchange between Japan and Korea, incorporating widely acclaimed Asian technologies and trends. Services and Products Offered https://cellbank.co.jp/hcps/safety_qualitycontrol/ ■About Cellbank The Company was founded in 2004 and has been providing cells since before "regenerative medicine" was widely recognized. In accordance with the "Act on the Safety of Regenerative Medicine, etc." enacted in 2014, the Company obtained a license for manufacturing specified cell-processed products from the Ministry of Health, Labour and Welfare in 2015. With a large-scale cell culture processing facility (CPC) of approximately 300m2, the Company manufactures and stores cell products. It provides contract manufacturing services for over 100 medical institutions nationwide offering regenerative medicine for skin (cosmetic field) and regenerative medicine for knees (orthopedic field), performing over 5,000 cultures annually. (As of January 2026). Leveraging our technological expertise, which includes support for implementation in medical institutions nationwide and over 20 years of cell storage experience, we will provide comprehensive support to our partner medical institut